Cinnabarinic acid provides hepatoprotection against non-alcoholic fatty liver disease

Data Supplement

• Supplemental Data -

  Supplemental Figure 1. Determination of (A) cell viability of AML12 cells treated with different concentrations of palmitic acid (PA) and oleic acid (OA) for 24 hrs.

  Supplemental Figure 2. Quantification of (A) triglyceride, (B) free fatty acid and (C) free fatty acid uptake in AML12 cells treated with 500µM BSA + DMSO (control), 30µM CA, 500µM PA, 500µM OA, 30µM CA+ 500µM PA/OA, 30µM CA after 500µM PA/OA.

  Supplemental Figure 3. Expression of mRNAs encoding genes involved in (A) free fatty acid transport, (B) fatty acid synthesis, (C) triglyceride synthesis, and (D) inflammation. 

  Supplemental Figure 4. CA treatment activates AhR signaling by upregulating Stc2 expression. mRNA expression of Stc2 and Cyp1a1 measured by qRT-PCR in (A) in vivo and (B) in vitro models of NAFLD, normalized to 18S rRNA. 

  Supplemental Table 1. Primer sequences for quantitative RT-PCR

  Supplemental Table 2. Primer sequences for ChIP